| Study |
Reference |
|
Broms (Controls exposed to other treatments), 2020
|
Broms Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 2020; 29:316-327
|
|
Broms (Controls unexposed, disease free), 2020
|
Broms Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 2020; 29:316-327
|
|
Bröms (controls unexposed, disease free), 2016
|
Bröms G Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy Clin Gastroenterol Hepatol. 2016a;14(2):234-241
|
|
Bröms (controls unexposed, sick), 2016
|
Bröms G Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy Clin Gastroenterol Hepatol. 2016a;14(2):234-241
|
|
Casanova, 2013
|
Casanova MJ Safety of thiopurines and anti-TNF-? drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:433-40
|
|
Chambers (Controls unexposed, disease free), 2019
|
Chambers Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study. PLoS ONE 2019; 14:e0223603
|
|
Chambers (Controls, sick), 2019
|
Chambers Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study. PLoS ONE 2019; 14:e0223603
|
|
De Lorenzo (Controls unexposed, disease free), 2020
|
De Lorenzo Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol. Res. 2020; 152:104583
|
|
De Lorenzo (Controls unexposed, sick), 2020
|
De Lorenzo Neonatal outcomes of children born to mothers on biological agents during pregnancy: State of the art and perspectives. Pharmacol. Res. 2020; 152:104583
|
|
Hoxha, 2017
|
Hoxha A Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-173
|
|
Hyrich, 2006
|
Hyrich Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 2006; 54:2701-2
|
|
Langen, 2014
|
Langen High rate of preterm birth in pregnancies complicated by rheumatoid arthritis. Am J Perinatol 2014; 31:9-14
|
|
Schnitzler (Unexposed control, disease free), 2011
|
Schnitzler F Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846-54
|
|
Schnitzler (Unexposed control, sick), 2011
|
Schnitzler F Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846-54
|
|
Seirafi, 2014
|
Seirafi M Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther 2014;40:363-73
|
|
Viktil (Controls exposed to other treatments), 2012
|
Viktil Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41:196-201
|
|
Viktil (Controls unexposed, NOS), 2012
|
Viktil Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41:196-201
|
|
Vinet (Unexposed controls, disease free), 2018
|
Vinet E Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study. Arthritis Rheumatol 2018;70:1565-1571
|
|
Vinet (Unexposed controls, sick), 2018
|
Vinet E Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study. Arthritis Rheumatol 2018;70:1565-1571
|
|
Weber-Schoendorfer, 2015
|
Weber-Schoendorfer C Pregnancy outcome after TNF-? inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39
|
